Department of Vermont Health Access
Pharmacy Benefits Management Program

DUR Board Meeting Agenda

February 19, 2019: 6:30 – 8:30 p.m.

- Executive Session 6:00 - 6:30
- Introductions and Approval of DUR Board Minutes 6:30 - 6:35
  (Public Comment Prior to Board Action)
- DVHA Pharmacy Administration Updates 6:35 - 6:40
- Medical Director Update 6:40 – 6:45
- Follow-up Items from Previous Meetings 6:45 – 6:55
  - Additional data on Vivitrol RetroDUR
- RetroDUR/ProDUR 6:55-7:10
  - Introduce: Evaluation of Opioid Prescribing for Chronic Pain
  - Data presentation: Co-prescribing of Opiates and Benzodiazepines

- Clinical Update: Drug Reviews 7:10-7:35
  (Public comment prior to Board action)

  Abbreviated New Drug Reviews
  None at this time

Full New Drug Reviews
- Doptelet® (avatrombopag) (Included in the Platelet Stimulating Agents
  Therapeutic Drug Class review)
- Jivi® (recombinat) (Included in the Hemophilia Factor Deficiency
  Therapeutic Drug Class review)
- Lokelma® (sodium zirconium cyclosilicate)
- Mulpleta® (lusutrombopag) (Included in the Platelet Stimulating Agents
  Therapeutic Drug Class review)
- Orilissa® (elagolix)
- Perseris® (risperidone)
- Takhzyro® (lanadelumab-flyo) (Included in the Hereditary Angioedema Therapeutic
  Drug Class review)

- New Managed Therapeutic Drug Classes 7:35-7:45
  (Public comment prior to Board action)
  - Platelet Stimulating Agents

- Therapeutic Drug Classes – Periodic Review 7:45 – 8:25
Atopic Dermatitis
• Gaucher Disease
• Hemophilia Factor Deficiency
• Hereditary Angioedema
• Muscular Dystrophy
• Pancreatic Enzymes
• Prenatal Vitamins
• Psoriasis Nonbiologic Oral and Topical

- Review of Newly-Developed/Revised Criteria 8:25 – 8:25

- General Announcements 8:25 – 8:30
  Selected FDA Safety Alerts
  FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab)

- Adjourn 8:30